Alopecia universalis with twenty-nail dystrophy (trachyonychia)
- Author(s): Jr, Peter Chien
- Kovich, Olympia I
- et al.
Alopecia universalis with twenty-nail dystrophy (trachyonychia)Department of Dermatology, New York University
Peter Chien Jr. MD PhD, Olympia I Kovich MD
Dermatology Online Journal 14 (5): 24
A 43-year-old man presented with long-standing trachyonychia of all 20 nails, noted worsening of his nail disease after the onset of alopecia universalis 18 months ago prior to presentation. Trachyonychia can be associated with alopecia universalis although the treatment strategies of both conditions differ. The principle of treating trachyonychia may involve regulating the differentiation of keratinocytes and/or reducing inflammation in the nail fold or nail matrix. The treatment of alopecia universalis involves immunomodulation.
A 43-year-old man initially presented to the NYU Dermatology Associates in April, 2007, for evaluation of nail ridges. The nail ridges have been present for 10 years but have worsened 18 months ago after the onset of hair loss over his entire body. He used fluocinonide lotion previously for the hair loss.
Past medical history and a review of systems were noncontributory. His children have eczema. He takes no medications.
The hair on the scalp, face, and body was absent. All 20 nails exhibited longitudinal ridges and were rough in texture. Some nails also exhibited onychoschizia and distal onycholysis.
|Figure 1||Figure 2|
Trachyonychia clinically appears as if the nails have been sandpapered in the longitudinal direction, which leaves a rough-ridged texture. Sometimes the terms trachyonychia and 20-nail dystrophy are used interchangeably in the literature. However, 20-nail dystrophy should only be used when all of the nails are affected. The cause of trachyonychia is often idiopathic, but when it appears in association with another condition, alopecia areata would be the most common . One study of alopecia areata in children observed that 46 percent also had nail abnormalities and 12 percent specifically had trachyonycia . It has been suggested that trachyonychia may herald the onset of alopecia areata , which is consistent with our patient's clinical course. Other associated conditions include lichen planus, psoriasis, immunoglobulin A deficiency, atopic dermatitis, and ichthyosis vulgaris .
Histopathologically, the proximal nail fold and nail matrix have been described to be spongiotic, with a mild lymphocytic infiltrate although occasionally lichenoid or psoriatic changes can be observed as well, which corresponds to the associated disease states [1, 3, 5]. When lichen planus and psoriasis were clinically and histopathologically excluded, spongiotic dermatitis in the nail matrix and nail bed with column-like parakeratosis in the nail plate was present when the trachyonychia was due to alopecia areata, atopic dermatitis, or an idiopathic cause . However, another group found that in 40 of 1095 patients with alopecia areata, one had a nail biopsy with histopathologic changes of lichen planus. Therefore, nail biopsies may be useful when the clinical diagnosis is obscure .
Treatment for trachyonychia associated with alopecia universalis is challenging. Tazorotene applied overnight to the nail plate, nail folds, and periungual areas for 3 months resulted in acceptable clinical and functional improvement, with the side effects of peeling and erythema of proximal nail fold skin . Trachyonychia due to psoriasis was successfully treated with acitretin at 0.3 mg/kg/day for three months . Topical 5-fluorouracil and cyclosporin also have been used to treat trachyonychia associated with psoriasis whereas prednisolone, antimalarials, and etretinate have been used to treat trachyonychia associated with lichen planus . Intralesional triamcinolone has been used with some success in idiopathic trachyonychia in 4 children, 1 of whom had 20 nails involved and a patch of alopecia areata . Trachyonychia may spontaneously resolve after several years regardless of treatment .
Alopecia universalis is the severe form of alopecia areata that results in a complete non-scarring loss of hair of the scalp and body. It occurs equally in men and women, but children and adolescents are more frequently affected . Like alopecia areata limited to patches on the scalp, it is thought to be an autoimmune phenomenon ; it can be associated with thyroid disease or atopic dermatitis . It is also associated with certain HLA alleles [14, 15] and T cells also may be involved in the pathogenesis. Although the precise mechanism is unknown, case reports of alopecia universalis developing after hepatitis C treatment with pegylated interferon and ribavirin , after treatment of rheumatoid arthritis with adalimumab , and in association with HIV infection [18-21] point toward a derangement of the immune system. Psychosocial stress has been implicated as a cause although the study employed patient ratings in a retrospective fashion . Nevertheless, one group reported success in an uncontrolled study with hypnotherapy either as an adjunct or as monotherapy and observed hair regrowth of at least 75 percent in 12 of 28 patients that were refractory to conventional treatments . Nine of these patients experienced complete regrowth, which included 4 patients with alopecia universalis. A neurologic basis is supported in a case report of alopecia universalis that spared a single patch of hair in a denervated right axilla where a lymphadenectomy was performed, which severed cutaneous branches of the intercostobrachial nerve . This patient also had 18-nail dystrophy with longitudinal ridges This case study suggested a neural mechanism interfacing with the immune system akin to vitiligo.
Treatment of alopecia universalis is based on immunomodulation. Although mixed results from case studies have been observed with topical imiquimod [24, 25], topical tacrolimus is a reported failure [26, 27]. Topical clobetasol and diphenylcyclopropenone (a topical sensitizer) have shown some efficacy [28, 29]. Systemically, oral, intramuscular, or intravenous pulse glucocorticoids [30-32], methotrexate , and efalizumab , have shown efficacy in treating alopecia universalis whereas etanercept [35, 36] did not appear to be effective. A retrospective study with PUVA photochemotherapy showed some efficacy as well . Systemic treatments for unrelated conditions leading to serendipitous resolution of alopecia universalis include allogeneic hematopoietic stem-cell transplantation in a patient with chronic myeloid leukemia  and injection with recombinant human bone morphogenetic protein 2 to aid in healing of a fractured tibia . Bone morphogenetic proteins are members of the TFG- superfamily and may be involved in the life cycle of the hair follicle or play a role in T-cell maturation in the thymus.
References1. Grover C, et al. Longitudinal nail biopsy: utility in 20-nail dystrophy. Derm Surg 2003; 29:1125
2. Tosti A, et al. Prevalence of nail abnormalities in children with alopecia areata. Pediatr Dermatol 1994; 11:112
3. Tosti A, et al. Is trachyonychia, a variety of alopecia areata, limited to the nails? J Invest Dermatol 1995; 104:27S
4. Scheinfeld NS. Trachyonychia: a case report and review of manifestations, associations, and treatments. Cutis 2003; 71:299
5. Tosti A, et al. Trachyonychia associated with alopecia areata: a clinical and pathologic study. J Am Acad Dermatol 1991; 25:266
6. Braun-Falco O, et al. Trachyonychia: 20-nail dystrophy. Hautarzt 1981; 32:17
7. Soda R, et al. Treatment of trachyonychia with tazarotene. Clin Exp Dermatol 2005; 30:301
8. Tosti A, et al. Occupational trachyonychia due to psoriasis: report of a case successfully treated with oral acitretin. Contact Derm 2006; 54:123
9. Khoo BP, Giam YC. A pilot study on the role of intralesional triamcinolone acetonide in the treatment of pitted nails in children. Singapore Med J 2000; 41:66
10. Sakata S, et al. Follow up of 12 patients with trachyonychia. Australas J Dermatol 2006; 47:166
11. Papadopoulos AJ, et al. Alopecia areata: pathogenesis, diagnosis, and therapy. Am J Clin Dermatol 2000; 1:101
12. Alexis AF, et al.Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol 2004; 14:364
13. Goh C, et al. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 2006; 20:1055
14. Aliagaoglu C, et al. Association between alopecia areata and HLA Class I and II in Turkey. J Dermatol 2005; 32:711
15. Xiao FL, et al. Association of HLA class I alleles with aloplecia areata in Chinese Hans. J Dermatol Sci 2006; 41:109
16. Demirturk N, et al. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Eur J Dermatol 2006; 16:579
17. Garcia Bartels N, et al. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 2006; 142:1654
18. Werninghaus K, Kaminer MS. HIV and alopecia universalis. J Am Acad Dermatol 1993; 29:667
19. Stewart MI, Smoller BR. Alopecia universalis in an HIV-positive patient: possible insight into pathogenesis. J Cutan Pathol 1993; 20:180
20. Ostlere LS, et al. Alopecia universalis in a patient seropositive for the human immunodeficiency virus. J Am Acad Dermatol 1992; 27:630
21. Lafeuillade A, et al. Alopecia universalis in a homosexual man seropositive for the human immunodeficiency virus. J Acquir Immune Defic Syndr 1990; 3:1019
22. Gupta MA, et al. Stress and alopecia areata: a psychodermatologic study. Acta Derm Venereol 1997; 77:296
23. Willemsen R, et al. Hypnotherapeutic management of alopecia areata. J Am Acad Dermatol 2006; 55:233
24. Atkin DH, et al. Single patch of hair at a denervated site in a patient with alopecia universalis. J Am Acad Dermatol 1997; 37:796
25. D'Ovidio R, et al. Ineffectiveness of imiquimod therapy for Alopecia Totalis/Universalis. J Eur Acad Dermatol Venereol 2002; 16:416
26. Park SW, et al. Topical tacrolimus (FK506): treatment failure in four cases of alopecia universalis. Acta Derm Venereol 2002; 82:387
27. Feldmann KA, et al. Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol 2002; 147:1031
28. Tosti A, et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003; 49:96
29. Sotiriadis D, et al. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol 2007; 32:48
30. Bin Saif GA. Oral mega pulse methylprednisolone in alopecia universalis. Saudi Med J 2006; 27:717
31. Kurosawa M, et al. A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology 2006; 212:361
32. Assouly P, et al. Intravenous pulse methylprednisolone therapy for severe alopecia areata: an open study of 66 patients. Ann Dermatol Venereol 2003; 130:326
33. Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 2006; 55:632
34. Kaelin U, et al. Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol 2006; 55:529
35. Abramovits W, Losornio M. Failure of two TNF-alpha blockers to influence the course of alopecia areata. Skinmed 2006;5:177
36. Strober BE, et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol 2005; 52:1082
37. Whitmont KJ, Cooper AJ. PUVA treatment of alopecia areata totalis and universalis: a retrospective study. Australas J Dermatol 2003; 44:106
38. Seifert B, et al. Complete remission of alopecia universalis after allogeneic hematopoietic stem cell transplantation. Blood 2005; 105:426
39. Leslie KS, et al. Alopecia universalis treated with bone morphogenetic protein? Br J Dermatol 2006; 154:190
© 2008 Dermatology Online Journal